Detalles de la búsqueda
1.
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial.
Ann Oncol
; 35(3): 276-284, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38061428
2.
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Ann Oncol
; 33(5): 534-543, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35182721
3.
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Br J Surg
; 108(3): 308-314, 2021 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33608712
4.
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
Ann Oncol
; 31(2): 228-235, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31959339
5.
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Pharmacogenomics J
; 20(2): 350, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30659276
6.
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.
BMC Cancer
; 20(1): 392, 2020 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32375735
7.
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.
Ann Oncol
; 30(1): 109-114, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30357310
8.
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Pharmacogenomics J
; 18(3): 474-479, 2018 05 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28719596
9.
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Pharmacogenomics J
; 17(4): 344-350, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27139155
10.
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer
; 112(8): 1405-10, 2015 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25867274
11.
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Ann Oncol
; 26(8): 1685-91, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25935792
12.
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol
; 26(2): 313-20, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403582
13.
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Br J Cancer
; 111(11): 2051-7, 2014 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-25268370
14.
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Br J Cancer
; 111(1): 55-60, 2014 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24874478
15.
Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics.
Ann Oncol
; 30(4): 652-653, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30689705
16.
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
Ann Oncol
; 25(1): 171-6, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24299961
17.
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Ann Oncol
; 25(2): 366-71, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24347519
18.
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol
; 25(2): 339-45, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24347518
19.
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Ann Hematol
; 93(2): 267-77, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24292560
20.
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Br J Cancer
; 109(3): 589-96, 2013 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23868011